Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Housing & Urban Development Corp., Paras Defence and Space Technologies Ltd. and Waaree Energies Ltd. are some stocks that ...

IT services company Wipro reported 24% growth in its consolidated net profit at Rs 3,354 crore, while revenue from operations ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral ...